Fortive delivers exceptional free cash flow conversion at 175% of net income and has recovered to two consecutive earnings beats, but technical momentum has weakened — with on-balance volume in a declining trend — and the stock sits just 3.1% below its near-term resistance target with an unfavorable risk/reward, warranting a hold-and-wait posture.
Thesis pillars
- Exceptional Cash Flow Quality↑Improving
- Improving Earnings Execution↓Deteriorating
- Weakening Technical Momentum↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 25, 2026· older than 90 days
Fortive Corporation (FTV) Stock Analysis
Technology · Scientific & Technical Instruments
Sell if holding. Analyst target reached at $68.34 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single supplier components.
Fortive Corporation designs and markets professional instruments, software, and services through two segments: Intelligent Operating Solutions (FLUKE, ACCRUENT, GORDIAN brands) and Advanced Healthcare Solutions (ASP, LANDAUER, PROVATION brands), employing over 10,000 people... Read more
Sell if holding. Analyst target reached at $68.34 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single supplier components. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 90d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Fortive Corporation
About Fortive Corporation
Fortive Corporation restructured its portfolio on June 28, 2025 by separating its Precision Technologies segment as Ralliant Corporation, a tax-free spin-off, focusing the company on two segments: Intelligent Operating Solutions and Advanced Healthcare Solutions, with a workforce of over 10,000 professionals in approximately 50 countries. Intelligent Operating Solutions brands include FLUKE, SERVICECHANNEL, GORDIAN, ACCRUENT, and INDUSTRIAL SCIENTIFIC; Advanced Healthcare Solutions brands include ASP, CENSIS, FLUKE BIOMEDICAL, LANDAUER, and PROVATION.
Fortive earns revenue through sales of instruments, software, and services to tens of thousands of industrial and healthcare customers. Intelligent Operating Solutions supplies test and measurement tools, facility and asset lifecycle software, and connected worker safety solutions to electrical engineers, facility managers, EHS professionals, and maintenance technicians across manufacturing, utilities, and communications industries. Advanced Healthcare Solutions addresses sterilization, biomedical testing, radiation dosimetry, and clinical documentation needs for hospital and surgical center operators. The company sells through direct and distributor channels; government entities represent a portion of each segment's revenue under agreements subject to statutes that apply to companies doing business with governments. Some specialty components depend on single or limited suppliers, though no single raw material supplier is described as material in aggregate. Fortive competes across highly fragmented markets against both multinational suppliers and regional specialists.
Show full overview
The Advanced Healthcare Solutions segment produces medical devices regulated by the U.S. FDA under the Federal Food, Drug and Cosmetic Act, with modifications to cleared devices potentially requiring new 510(k) filings and associated FDA user fees. Products for the European Economic Area must conform to the Medical Devices Regulation effective May 26, 2021, with a CE certificate from a notified body required before market access; the UK separately requires a UKCA Certificate. This multi-jurisdictional framework subjects AHS manufacturing facilities to routine FDA inspection and comparable foreign authority audits throughout the product lifecycle, and may result in ongoing compliance costs as requirements evolve.
See also: Technology · Scientific & Technical Instruments
From Fortive Corporation's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Oct 28, 2026Recent Developments — Fortive Corporation
Latest news
- NEWS What Fortive (FTV) Said on Its Q3 Earnings Call - TradingView — TradingView Oct 28, 2026 neutral
- NEWS What Fortive (FTV) Said on Its Q3 Earnings Call - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
- NEWS Fortive Shares Jumping 6.8% on S&P 500 Premarket Movers for Oct. 28, 2026 - AlphaStreet — AlphaStreet Oct 28, 2026 positive
- NEWS Fortive jumps to 16-mth high as earnings beat estimates, outlook raised (FTV:NYSE) - Seeking Alpha — Seeking Alpha Oct 28, 2026 positive
- NEWS Fortive (NYSE:FTV) Sets New 1-Year High After Better-Than-Expected Earnings - MarketBeat — MarketBeat Oct 28, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-05T11:44:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle supplier components10-K Item 1: 'some components that require particular specifications or qualifications are dependent on a single supplier or a limited number of suppliers that can readily provide such components'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $68.34 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single supplier components. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $64.62. Score 5.8/10, moderate confidence.
Analyst target $58.35 reached (−14.6% from $68.34); no take-profit level is published. Prior stop was $64.62. Stop-loss: $64.62.
Concentration risk — Supplier: single supplier components; Analyst target reached - limited upside remaining; Near 52-week high (0.9% away).
Fortive Corporation trades at a P/E of 32.4 (forward 20.6). TrendMatrix value score: 5.5/10. Verdict: Sell.
22 analysts rate FTV, with a consensus score of 3.4/5. 14 analysts publish price targets averaging $67.
What does Fortive Corporation do?Fortive Corporation designs and markets professional instruments, software, and services through two segments:...
Fortive Corporation designs and markets professional instruments, software, and services through two segments: Intelligent Operating Solutions (FLUKE, ACCRUENT, GORDIAN brands) and Advanced Healthcare Solutions (ASP, LANDAUER, PROVATION brands), employing over 10,000 people across approximately 50 countries. After spinning off its Precision Technologies segment as Ralliant in June 2025, the company focuses on safety and productivity tools and clinical workflow solutions sold to industrial, healthcare, and government customers.